Journal
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE
Volume 9, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/jcdd9070203
Keywords
immune checkpoint inhibitors; cardiotoxicity; cardio-oncology; cancer-type-specific
Categories
Ask authors/readers for more resources
ICIs have shown great potential in cancer treatment, but their cardiotoxicity is a concerning issue. This systematic review reveals that cardiotoxicity related to ICIs varies with different types of cancer, suggesting the importance of personalized clinical strategies to maintain the cardiovascular health of cancer patients.
Immune checkpoint inhibitors (ICIs) are rapidly developing immunotherapy cancer drugs that have prolonged patient survival. However, ICIs-related cardiotoxicity has been recognized as a rare, but fatal, consequence. Although there has been extensive research based on different types of ICIs, these studies have not indicated whether cardiotoxicity is specific to a type of cancer. Therefore, we conducted a systematic review to analyze a variety of ICIs-related cardiotoxicity, focusing on different types of cancer. We found that the incidence of ICIs-related cardiac adverse events (CAEs) and common cardiotoxic manifestations vary with cancer type. This inspired us to explore the underlying mechanisms to formulate targeted clinical strategies for maintaining the cardiovascular health of cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available